The Other Stem Cell Debate
By Jamie Shreeve,
The New York Times
| 04. 10. 2005
Except for the three million human brain cells injected into his
cranium, XO47 is just an average green vervet monkey. He weighs about
12 pounds and measures 34 inches from the tip of his tail to the
sutured incision on the top of his head. His fur is a melange of black,
yellow and olive, with white underparts and a coal-black face. Until
his operation, two days before I met him, he was skittering about an
open-air enclosure on the grounds of a biomedical facility on the
Caribbean island of St. Kitts. Afterward, he was caged in a hut shared
with half a dozen other experimental monkeys, all of whom bore
identical incisions in their scalps. Judging from the results of
previous experiments, the human neural stem cells inserted into their
brains would soon take hold and begin to grow, their fibers reaching
out to shake hands with their monkey counterparts. The green vervets'
behavior was, and will remain, all monkey. To a vervet, eye contact
signals aggression, and when I peered into X047's cage, he took
umbrage, vigorously bobbing...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...